Biotest Aktiengesellschaft (XETRA:BIO) — Stock Price
Biotest Aktiengesellschaft (XETRA:BIO) is currently trading at €42.20 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €42.20 and €42.20. This page tracks Biotest Aktiengesellschaft's live share price on the XETRA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Biotest Aktiengesellschaft.
Biotest Aktiengesellschaft (BIO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Biotest Aktiengesellschaft's daily closing share price and trading volume on the XETRA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daily price history is not currently available for Biotest Aktiengesellschaft.
Biotest Aktiengesellschaft Income Statement — Revenue, Profit & Earnings by Year
Biotest Aktiengesellschaft's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €726.20 Million | €684.60 Million | €516.10 Million | €515.60 Million | €484.20 Million |
| Cost of Revenue | €502.40 Million | €404.30 Million | €391.20 Million | €434.90 Million | €354.10 Million |
| Gross Profit | €223.80 Million | €280.30 Million | €124.90 Million | €80.70 Million | €130.10 Million |
| Research & Development | €56.10 Million | €66.20 Million | €50.50 Million | €51.70 Million | €55.80 Million |
| SG&A | €38.40 Million | €30.60 Million | €31.70 Million | €30.10 Million | €28.20 Million |
| Total Operating Expenses | €129.30 Million | €136.80 Million | €133.40 Million | €132.80 Million | €132.60 Million |
| Operating Income | €94.50 Million | €143.50 Million | €-13.00 Million | €-47.10 Million | €-1.30 Million |
| EBITDA | €120.40 Million | €182.20 Million | €24.70 Million | €-18.30 Million | €16.00 Million |
| EBIT | €79.80 Million | €146.30 Million | €-11.00 Million | €-49.40 Million | €-13.60 Million |
| Interest Expense | €33.30 Million | €40.00 Million | €22.40 Million | €15.10 Million | €15.90 Million |
| Income Before Tax | €46.50 Million | €106.30 Million | €-30.90 Million | €-62.70 Million | €-30.00 Million |
| Income Tax Expense | €20.20 Million | €-20.70 Million | €800.00K | €700.00K | €1.40 Million |
| Net Income | €26.40 Million | €127.00 Million | €-31.70 Million | €-63.40 Million | €-31.40 Million |
Biotest Aktiengesellschaft Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Biotest Aktiengesellschaft's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €1.43 Billion | €1.41 Billion | €1.20 Billion | €1.10 Billion | €1.13 Billion |
| Total Current Assets | €809.50 Million | €756.50 Million | €619.40 Million | €522.20 Million | €556.30 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €11.70 Million | €10.40 Million | €20.00 Million | €13.10 Million | €17.90 Million |
| Net Receivables | €201.90 Million | €196.80 Million | €179.90 Million | €146.40 Million | €162.10 Million |
| Inventory | €479.50 Million | €419.10 Million | €293.80 Million | €244.60 Million | €290.10 Million |
| Property, Plant & Equipment | — | — | — | €476.70 Million | €311.30 Million |
| Goodwill | €6.00 Million | €6.00 Million | €7.20 Million | €7.10 Million | €7.10 Million |
| Total Liabilities | €903.30 Million | €912.00 Million | €831.90 Million | €723.80 Million | €689.70 Million |
| Total Current Liabilities | €160.10 Million | €385.30 Million | €130.20 Million | €106.40 Million | €105.60 Million |
| Long-term Debt | €538.50 Million | €329.50 Million | €540.50 Million | €473.40 Million | €438.20 Million |
| Net Debt | €489.40 Million | €581.70 Million | €457.70 Million | €391.90 Million | €397.80 Million |
| Total Stockholder Equity | €530.70 Million | €498.90 Million | €371.10 Million | €380.40 Million | €441.60 Million |
| Retained Earnings | €274.50 Million | €238.40 Million | €111.70 Million | €121.00 Million | €182.20 Million |
Biotest Aktiengesellschaft Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Biotest Aktiengesellschaft generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €60.90 Million | €-2.70 Million | €-40.50 Million | €33.90 Million | €-16.70 Million |
| Capital Expenditures | €28.70 Million | €33.40 Million | €29.30 Million | €18.20 Million | €27.00 Million |
| Free Cash Flow | €32.20 Million | €-36.10 Million | €-69.80 Million | €15.70 Million | €-43.70 Million |
| Investing Cash Flow | — | — | — | €-23.40 Million | €-14.60 Million |
| Financing Cash Flow | €-35.40 Million | €-6.80 Million | €89.60 Million | €22.60 Million | €42.00 Million |
| Dividends Paid | €1.60 Million | — | €800.00K | €800.00K | €800.00K |
| Stock-Based Compensation | — | €-26.50 Million | €1.00 Million | — | — |
| Depreciation | €40.60 Million | €35.90 Million | €35.80 Million | €31.10 Million | €29.60 Million |
| Change in Cash | €-300.00K | €-8.50 Million | €12.20 Million | €33.10 Million | €10.50 Million |
Biotest Aktiengesellschaft Earnings History — EPS Actual vs. Analyst Estimates
Track Biotest Aktiengesellschaft's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 10, 2025 | — | — | — |
| Aug 04, 2025 | — | — | — |
| May 12, 2025 | -0.54 | — | — |
| Mar 26, 2025 | -0.09 | — | — |
| Nov 07, 2024 | -0.24 | — | — |
| Jul 30, 2024 | 0.25 | — | — |
| May 07, 2024 | 0.75 | — | — |
| Mar 28, 2024 | 0.98 | — | — |